SCHEMBL267161

SCHEMBL267161

COc1ccc(C(=O)Nc2ccc(N3CCOCC3)cc2C(=O)NN=Cc2ccc(C)c(C)c2)cc1OC

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.57
KDM4E B2RXH2 8/20 0.57
ALDH1A1 P00352 7/20 0.57
KMT2A Q03164 6/20 0.57
MEN1 O00255 4/20 0.57
POLB P06746 3/20 0.57
PKM P14618 4/20 0.55
TDP1 Q9NUW8 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
HTT P42858 2/20 0.48
OPRK1 P41145 1/20 0.48
GAA P10253 2/20 0.48
ABCB1 P08183 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
BLM P54132 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267160 1.00 MAPT (0.57) MAPTKDM4EALDH1A1KMT2AMEN1
SCHEMBL267988 0.92 NPC1 (0.52) MAPTKDM4EALDH1A1KMT2AMEN1
SCHEMBL267987 0.92 NPC1 (0.52) MAPTKDM4EALDH1A1KMT2AMEN1
SCHEMBL267995 0.91 MAPT (0.57) MAPTKDM4EALDH1A1KMT2AMEN1
SCHEMBL267996 0.91 MAPT (0.57) MAPTKDM4EALDH1A1KMT2AMEN1
SCHEMBL268716 0.90 MAPT (0.61) MAPTKDM4EALDH1A1KMT2AMEN1
SCHEMBL268717 0.90 MAPT (0.61) MAPTKDM4EALDH1A1KMT2AMEN1
SCHEMBL266737 0.84 RAB9A (0.59) MAPTKDM4EALDH1A1KMT2AMEN1
SCHEMBL266736 0.84 RAB9A (0.59) MAPTKDM4EALDH1A1KMT2AMEN1
SCHEMBL268310 0.83 RAB9A (0.58) MAPTKDM4EALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 MAPT 4195/4885KDM4E 4468/4885ALDH1A1 3022/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MAPT 4648/4885KDM4E 4535/4885ALDH1A1 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.